CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This study was a single-arm, multi-center, phase II study, which is aimed to evaluate the
efficacy and safety of CM082 combined with JS001 as the second-line treatment of advanced
small cell lung cancer. Eligible patients will receive CM082 tablets 150mg once daily orally
in combination with JS001 (240mg, intravenously) every 21 days. Treatment continues until
disease progresses , intolerable toxicity, or withdraw.